Department of Microbiology, Federal University of Minas Gerais, Av. Antônio Carlos, Belo Horizonte, MG, 6627, 30270-901, Brazil.
Department of Biochemistry and Immunology, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.
Probiotics Antimicrob Proteins. 2024 Jun;16(3):737-751. doi: 10.1007/s12602-023-10076-4. Epub 2023 Apr 25.
Next-generation microorganisms have recently gained prominence in the scientific community, mainly due to their probiotic and postbiotic potentials. However, there are few studies that investigate these potentials in food allergy models. Therefore, the present study was designed to evaluate the probiotic potential of Akkermansia muciniphila BAA-835 in an ovalbumin food allergy (OVA) model and also analyse possible postbiotic potential. To access the probiotic potential, clinical, immunological, microbiological, and histological parameters were evaluated. In addition, the postbiotic potential was also evaluated by immunological parameters. Treatment with viable A. muciniphila was able to mitigate weight loss and serum levels of IgE and IgG1 anti-OVA in allergic mice. In addition, the ability of the bacteria to reduce the injury of the proximal jejunum, the eosinophil and neutrophil influx, and the levels of eotaxin-1, CXCL1/KC, IL4, IL6, IL9, IL13, IL17, and TNF, was clear. Furthermore, A. muciniphila was able to attenuate dysbiotic signs of food allergy by mitigating Staphylococcus levels and yeast frequency in the gut microbiota. In addition, the administration of the inactivated bacteria attenuated the levels of IgE anti-OVA and eosinophils, indicating its postbiotic effect. Our data demonstrate for the first time that the oral administration of viable and inactivated A. muciniphila BAA-835 promotes a systemic immunomodulatory protective effect in an in vivo model of food allergy to ovalbumin, which suggests its probiotic and postbiotic properties.
新一代微生物最近在科学界引起了关注，主要是因为它们具有益生菌和后生元的潜力。然而，很少有研究调查这些潜力在食物过敏模型中的作用。因此，本研究旨在评估阿克曼氏菌 BAA-835 在卵清蛋白食物过敏（OVA）模型中的益生菌潜力，并分析其可能的后生元潜力。为了评估益生菌潜力，评估了临床、免疫、微生物和组织学参数。此外，还通过免疫学参数评估后生元潜力。用活菌 A. muciniphila 治疗能够减轻过敏小鼠的体重减轻和血清 IgE 和 IgG1 抗 OVA 水平。此外，细菌减少近端空肠损伤、嗜酸性粒细胞和中性粒细胞浸润以及嗜酸性粒细胞趋化因子-1、CXCL1/KC、IL4、IL6、IL9、IL13、IL17 和 TNF 水平的能力是明确的。此外，A. muciniphila 通过减轻肠道微生物群中葡萄球菌水平和酵母频率来减轻食物过敏的失调迹象。此外，灭活细菌的给药减轻了 IgE 抗 OVA 和嗜酸性粒细胞的水平，表明其具有后生元作用。我们的数据首次表明，口服活菌和灭活的 A. muciniphila BAA-835 在卵清蛋白食物过敏的体内模型中促进了系统性免疫调节保护作用，这表明其具有益生菌和后生元特性。
